Vatelizumab (GBR500) is a monoclonal antibody targeting the α2 subunit (CD49b) of very late antigen-2 (VLA-2). Vatelizumab can be used for the research of multiple sclerosis[1].
References
[1] Johanna Breuer, et al. VLA-2 blockade in vivo by vatelizumab induces CD4+FoxP3+ regulatory T cells. Int Immunol. 2019 May 21;31(6):407-412. DOI:10.1093/intimm/dxz018
